Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of TransCode Therapeutics, Inc. (NASDAQ:RNAZ), it sends a ...
Split designed to achieve compliance with Nasdaq minimum bid price requirements BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA ...
BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical-stage oncology company, announced today that its Board of Directors has approved a reverse stock split at a ratio of 1-for-28. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results